Safe coadministration of terbinafine and terfenadine: A placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 3, 1996, Pages 275-283

  Robbins, Bruce ^b   Chang, Cheng Tao ^b   Cramer, Jeffery A ^b   Garreffa, Stephen ^b   Hafkin, Barry ^b   Hunt, Thomas L ^b   Meligeni, John ^a  

^a Sandoz Pharma Ltd   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PLACEBO; TERBINAFINE; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; NAPHTHALENES; REFERENCE VALUES; TERFENADINE;

EID: 0029880918     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)80005-1     Document Type: Article

References (15)

1. Birnbaum J. Pharmacology of allylamines. J Am Acad Dermatol 1990;23:782-5.
2. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992;126(suppl 39):61-9.
3. Ryder NS. Squalene epoxidase as a target for the allylamines. Biochem Soc Trans 1991;19:774-7.
4. Lyman CA, Walsh TJ. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:8-34.
5. Breckenridge A. Clinical significance of interactions with antifungal agents. Br J Dermatol 1992;126(suppl 39):19-22.
6. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. CLIN PHARMACOL THER 1993;53:630-6.
7. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
8. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264: 2788-90.
9. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993;95:445-6.
10. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Torsades de pointes after terfenadine-itraconazole interaction. BMJ 1993;306:186.
11. Garteiz DA, Hook RH, Walker BJ, Okerholm RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 1982;32: 1185-90.
12. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-70.
13. Coutant J, Westmark P, Nardella P, Walter S, Okerholm R. Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991;570:139-48.
14. Denouel J, Keller HP, Schaub P, Delaborde C, Humbert H. Determination of terbinafine and its desmethyl metabolite in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995;663:353-9.
15. Zehender H, Cabiac MD, Denouel J, et al. Elimination kinetics of terbinafine from human plasma and tissues after multiple dose administration, and comparison with three main metabolites. Drug Invest 1994;8:203-10.